NOT-DK-20-018: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK

In order to rapidly improve our understanding and available control measures for COVID-19, NIDDK is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:

Microsoft AI for Health

This grant program provides Azure cloud and High-Performance Computing capabilities. Our team of AI for Health data science experts, whose mission is to improve the health of people and communities worldwide, is also open to collaborations with COVID-19 researchers as they tackle this critical challenge. More broadly, Microsoft’s research scientists across the world, spanning computer science, biology, medicine, and public health, will also be available to provide advice and collaborate per mutual interest.

NOT-DC-20-004: Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)

National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NIDCD’s scientific mission areas of hearing, balance, taste, smell, voice, speech and language.

NOT-CA-20-042: Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)

The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa.

NEH CARES: Cultural Organizations

UA may submit one application as a parent organization and UA may submit one application for each Independent Component (IC). This limited submission is Institutionally Coordinated via this accelerated internal competition. We are requesting submission for both the UA parent organization submission and from each independent component to ensure that we do not exceed our submission limits. Contact RDS with any questionsUA: M. McquirterPoetry Center IC: S. KortemeierCenter for Creative Photography IC: A. PeregoyUniversity of Arizona Press IC: K.

External Deadline
05/11/2020
Internal Deadline
April 29, 2020

NOT-CA-20-043: Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)

The NCI Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs encourage applications from small businesses with NCI-funded active NCI SBIR/STTR awards that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19) in cancer patients, cancer survivors, and in the general population. A compelling rationale should be presented and linked to an appropriate research plan to generate data in support of the new proposed use. Areas of interest include but not limited to:

NOT-AT-20-011: Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)

NCCIH, NIA, and NIAAA are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.